222 related articles for article (PubMed ID: 29078846)
1. 11β-Hydroxysteroid Dehydrogenase Type 1 in Obese Subjects With Type 2 Diabetes Mellitus.
Li X; Wang J; Yang Q; Shao S
Am J Med Sci; 2017 Oct; 354(4):408-414. PubMed ID: 29078846
[TBL] [Abstract][Full Text] [Related]
2. 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
Stulnig TM; Waldhäusl W
Diabetologia; 2004 Jan; 47(1):1-11. PubMed ID: 14652720
[TBL] [Abstract][Full Text] [Related]
3. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
4. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
5. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Hughes KA; Webster SP; Walker BR
Expert Opin Investig Drugs; 2008 Apr; 17(4):481-96. PubMed ID: 18363514
[TBL] [Abstract][Full Text] [Related]
6. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Morgan SA; Tomlinson JW
Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance.
Shao S; Zhang X; Zhang M
Biochem Biophys Res Commun; 2016 Sep; 478(1):474-480. PubMed ID: 27268236
[TBL] [Abstract][Full Text] [Related]
8. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
Valsamakis G; Anwar A; Tomlinson JW; Shackleton CH; McTernan PG; Chetty R; Wood PJ; Banerjee AK; Holder G; Barnett AH; Stewart PM; Kumar S
J Clin Endocrinol Metab; 2004 Sep; 89(9):4755-61. PubMed ID: 15356090
[TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
11. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice.
Wang L; Liu J; Zhang A; Cheng P; Zhang X; Lv S; Wu L; Yu J; Di W; Zha J; Kong X; Qi H; Zhong Y; Ding G
PLoS One; 2012; 7(7):e40056. PubMed ID: 22768329
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes.
Abdallah BM; Beck-Nielsen H; Gaster M
Eur J Clin Invest; 2005 Oct; 35(10):627-34. PubMed ID: 16178882
[TBL] [Abstract][Full Text] [Related]
13. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
14. Application of ELISA Technique and Human Microsomes in the Search for 11
Kupczyk D; Studzińska R; Bilski R; Woźniak A
Biomed Res Int; 2019; 2019():5747436. PubMed ID: 31214617
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
16. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
17. 11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle.
Nair S; Lee YH; Lindsay RS; Walker BR; Tataranni PA; Bogardus C; Baier LJ; Permana PA
Diabetologia; 2004 Jun; 47(6):1088-95. PubMed ID: 15156315
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
19. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
20. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]